AIM: To present novel frameshift mutation c.31delC [p.L11X] in the MLH1 gene identified in an extended Bulgarian hereditary non-polyposis colorectal cancer (HNPCC) family and to analyze the molecular and clinical findings within the pedigree concerning the proposal of adequate individual prophylactic strategy for all mutation carriers. METHODS: The pedigree of the family consists of 42 members in four generations. Search for mutations in the MLH1 and hMSH2 genes was performed in the proband. After PCR amplification of all exons including flanking intronic regions, amplicons were directly sequenced. RESULTS: The mutation was found in nine from the thirteen pedigree members who signed informed consent to participate in the study. In three adenocarcinomas, microsatellite instability and lack of the MLH1 protein expression were detected. The only one tubulovillous adenoma analyzed was microsatellite stable and the MLH1 protein showed an intact staining. CONCLUSION: The newly described mutation c.31delC is HNPCC causative. Besides the typical clinical features of the syndrome, we found a specific pathologic manifestation such as moderate to high differentiated adenocarcinomas of the colon. One of the mutation carriers developed a benign giant cell soft tissue tumor. The primary tumor localizations were frequently extracolonic and detailed yearly gastrointestinal and gynecological examinations have been proposed to the mutation carriers. We emphasize the importance of including the HNPCC genetic counseling and testing as well in the following surveillance of all patients at risk in the services covered by the health insurance in Bulgaria.
AIM: To present novel frameshift mutation c.31delC [p.L11X] in the MLH1 gene identified in an extended Bulgarian hereditary non-polyposis colorectal cancer (HNPCC) family and to analyze the molecular and clinical findings within the pedigree concerning the proposal of adequate individual prophylactic strategy for all mutation carriers. METHODS: The pedigree of the family consists of 42 members in four generations. Search for mutations in the MLH1 and hMSH2 genes was performed in the proband. After PCR amplification of all exons including flanking intronic regions, amplicons were directly sequenced. RESULTS: The mutation was found in nine from the thirteen pedigree members who signed informed consent to participate in the study. In three adenocarcinomas, microsatellite instability and lack of the MLH1 protein expression were detected. The only one tubulovillous adenoma analyzed was microsatellite stable and the MLH1 protein showed an intact staining. CONCLUSION: The newly described mutation c.31delC is HNPCC causative. Besides the typical clinical features of the syndrome, we found a specific pathologic manifestation such as moderate to high differentiated adenocarcinomas of the colon. One of the mutation carriers developed a benign giant cell soft tissue tumor. The primary tumor localizations were frequently extracolonic and detailed yearly gastrointestinal and gynecological examinations have been proposed to the mutation carriers. We emphasize the importance of including the HNPCC genetic counseling and testing as well in the following surveillance of all patients at risk in the services covered by the health insurance in Bulgaria.
Authors: R J Scott; M McPhillips; C J Meldrum; P E Fitzgerald; K Adams; A D Spigelman; D du Sart; K Tucker; J Kirk Journal: Am J Hum Genet Date: 2000-12-07 Impact factor: 11.025
Authors: Yvonne M C Hendriks; Andrea E de Jong; Hans Morreau; Carli M J Tops; Hans F Vasen; Juul Th Wijnen; Martijn H Breuning; Annette H J T Bröcker-Vriends Journal: CA Cancer J Clin Date: 2006 Jul-Aug Impact factor: 508.702
Authors: Timm Goecke; Karsten Schulmann; Christoph Engel; Elke Holinski-Feder; Constanze Pagenstecher; Hans K Schackert; Matthias Kloor; Erdmute Kunstmann; Holger Vogelsang; Gisela Keller; Wolfgang Dietmaier; Elisabeth Mangold; Nicolaus Friedrichs; Peter Propping; Stefan Krüger; Johannes Gebert; Wolff Schmiegel; Josef Rueschoff; Markus Loeffler; Gabriela Moeslein Journal: J Clin Oncol Date: 2006-08-14 Impact factor: 44.544
Authors: Marie Luise Bisgaard; Anne Charlotte Jäger; Torben Myrhøj; Inge Bernstein; Finn Cilius Nielsen Journal: Hum Mutat Date: 2002-07 Impact factor: 4.878
Authors: A Apessos; M Mihalatos; I Danielidis; G Kallimanis; N J Agnantis; J K Triantafillidis; G Fountzilas; P A Kosmidis; E Razis; V A Georgoulias; G Nasioulas Journal: Br J Cancer Date: 2005-01-31 Impact factor: 7.640